High expression levels of MMP-1 (P=0.00012) and MMP-9 (P=0.00022) were predictive of a decreased RFS in endocrine treated ER+ human breast cancer patients (n=690) as shown in Figure 1d. This evidence concerns the gene MMP9 and breast carcinoma.